Jazz Pharmaceuticals announced that the Phase 3 LAGOON trial of Zepzelca (lurbinectedin) for second-line treatment of relapsed metastatic small cell lung cancer (SCLC) did not meet its primary endpoint of overall survival. The trial compared Zepzelca alone or with irinotecan against standard treatments but showed no significant survival benefit. However, no new safety concerns emerged, and the drug remains approved for first-line maintenance treatment based on earlier positive results. Jazz will discuss next steps with the FDA regarding post-marketing requirements for the second-line use, and the trial outcome does not affect the company's 2026 financial guidance.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
